Suven Life Sciences Q2 FY27 Share Price & Earnings Call Analysis

Part of: Nifty Microcap 250 · Nifty Total Market

₹268.65-0.09% today
Market cap
₹7,591 Cr
ROE
-81.52%
Price to sales
834.17
Debt to equity
0.04
52W high / low
₹392 / ₹127
Sales growth (5Y)
-12.01%
EBITDA margin
-4366.92%
Net profit margin
-4020.82%
Promoter holding
65.47%
Sales (last year)
₹9 Cr

Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.[1] [2]

Guidance scorecard · Q2 FY27 call

What Suven Life Sciences's management guided
and where it ranks in Healthcare Services

RevenueQ3 FY20 call

10–20%
  • Suven Pharma expects 15-20% growth in revenue for FY21 and beyond, based on expanded activities and capacities.
  • Growth outlook is driven by a mix of contract manufacturing, specialty chemicals, new ANDA filings, and commercial CRAMS.
  • The company acknowledges variability in quarter-to-quarter performance but maintains confidence in overall annual growth.
  • FROM FY21 onwards, growth is expected to improve further with new infrastructure and expanded activities.
  • The capacity utilization is effectively 100%, with a mix-and-match product approach allowing flexibility.

2 more points from Suven Life Sciences's call on revenue

Create a free account to keep reading this call

Full Q3 FY20 analysis

MarginsQ3 FY20 call

Flat

See what Suven Life Sciences said on margins — free account, 30 seconds.

Full Q3 FY20 analysis

CapexQ3 FY20 call

Planned
  • Suven Pharma has a total planned CAPEX of Rs. 320 crore, with Rs. 160 crore already spent and the balance expected to be spent by the end of FY20.
  • For FY21, only replacement CAPEX of Rs. 50 crore is planned; no major new CAPEX is planned currently.
  • The Rs. 320 crore CAPEX spans specialty chemicals, intermediates, formulation, and niche API (backward integration for internal and CRAMS customers) but not large-scale API commercial production.
  • Capacity expansion is focused on reactor capacity (about 300 kiloliters), supporting a mix-and-match batch production model rather than fixed product capacity.

2 more points from Suven Life Sciences's call on capex

Create a free account to keep reading this call

Full Q3 FY20 analysis

FundraisingQ3 FY20 call

Planned

See what Suven Life Sciences said on fundraising — free account, 30 seconds.

Full Q3 FY20 analysis

Order bookQ3 FY20 call

  • Suven Pharma's commercial supply fluctuates with product demand, making it difficult to gauge a fixed order book or capacity utilization on a monthly basis.
  • Capacity utilization is effectively 100% in terms of mix and match product manufacturing, but not continuously occupied by a single product.
  • Management expects 15-20% growth next year based on the current number of projects and past performance, indicating a healthy order pipeline.

2 more points from Suven Life Sciences's call on the order book

Create a free account to keep reading this call

Full Q3 FY20 analysis

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Services
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. IndegeneGood growth
    3

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Suven Life Sciences latest results (Sep 2026)

Revenue

₹1 Cr

+30% YoY

Net profit

₹-107 Cr

Operating margin

-9242%

EPS

₹-3.78

What management said on the call →

Suven Life Sciences shareholding (Sep 2026)

Promoters

65.47%

−4.61 pp QoQ

FIIs

0.45%

−0.11 pp QoQ

DIIs

2.17%

−0.76 pp QoQ

Public

31.89%

+5.47 pp QoQ

Peers

Healthcare Services companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹870 Cr—
240%+Flat₹576 Cr21.9
3Indegene20–40%Up 2%+₹16,058 Cr37.7
420–40%Up 2%+₹1,716 Cr17.0
520–40%Up 2%+₹622 Cr20.9
620–40%Flat₹1.23L Cr54.1

Sign up free to see every company in the sector ranking and track Suven Life Sciences.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services ranking

Financials of Suven Life Sciences

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Suven Life Sciences

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +69.56%69.56%70.26%70.26%70.26%70.26%70.26%67.36%67.36%70.15%70.08%65.47%
FIIs +0.54%0.46%0.45%0.33%0.34%0.25%0.58%1.17%1.07%0.91%0.56%0.45%
DIIs +0.01%1.05%1.05%1.05%1.05%0.01%0.03%3.39%3.39%4.62%2.93%2.17%
Public +29.88%28.91%28.21%28.34%28.35%29.47%29.12%28.07%28.18%24.32%26.42%31.89%
No. of Shareholders74,00368,95966,11663,97563,53764,60366,15964,92164,38163,91566,79167,431

Financials of Suven Life Sciences

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +3221321213241
YoY Sales growth-30%-18%-8%-73%-16%-34%-38%+85%-64%+75%+3%+91%+30%
Expenses +27493332554145538110652136112
Operating Profit-24-46-30-31-52-39-44-51-80-103-51-132-111
OPM %-768%-1,885%-1,267%-3,024%-2,032%-2,435%-2,981%-2,714%-8,671%-3,678%-3,331%-3,711%-9,242%
Other Income +13644421143787
Interest0000000000000
Depreciation2221121111222
Profit before tax-13-42-28-28-50-39-44-52-77-102-46-128-107
Tax %0%0%-4%0%0%0%0%0%0%0%0%0%0%
Net Profit +-13-42-27-28-50-39-44-52-77-102-46-128-107
EPS in Rs-0.58-1.91-1.22-1.29-2.28-1.79-2.01-2.36-3.40-4.48-1.73-4.83-3.78

Financials of Suven Life Sciences

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +5214995436252861313121412779
Sales growth-4%+9%+15%-54%-96%+7%-12%+14%-14%-43%+7%+55%
Expenses +36139841442730012893134139140172291406
Operating Profit159102129198-14-116-80-122-126-128-166-284-397
OPM %31%20%24%32%-5%-917%-593%-1,032%-929%-1,094%-2,487%-3,999%-4,367%
Other Income +91921232714851429111424
Interest5665211100001
Depreciation121821211144476667
Profit before tax152981231960-106-77-122-118-106-161-276-382
Tax %28%26%29%37%15,038%-11%-7%0%0%-1%0%0%
Net Profit +1097287124-24-94-72-122-118-105-161-276-382
EPS in Rs7.875.206.318.95-1.73-6.82-5.22-7.73-5.42-4.82-7.37-10.48-14.82
Dividend Payout %7%35%15%15%-80%0%0%0%0%0%0%0%

Financials of Suven Life Sciences

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital13131313131313152222222628
Reserves547583654755226131958235424888565425
Borrowings +10983713436532101716
Other Liabilities +105747811862331691214251637
Total Liabilities773751816919303182128108389285135624506
Fixed Assets +1723053063082225213837286073115
CWIP10771025005400044
Investments00301279223004546762218114
Other Assets +494439199308581571032230518153367374
Total Assets773751816919303182128108389285135624506

Financials of Suven Life Sciences

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +1436810970-53-135-96-128-116-115-155-300
Cash from Investing Activity +-110-39-311-13014656-22-24894155-462
Cash from Financing Activity +179-68-30-525335146396-1-1757
Net Cash Flow212-39-23217-1814-5-432-22-1-5
Free Cash Flow25107928-92-137-102-147-119-113-193-305
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit113%93%111%57%262%114%119%104%91%95%93%106%

Financials of Suven Life Sciences

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days28393136366484022407378
Inventory Days1651832223290
Days Payable897891134
Cash Conversion Cycle105144162231366484022407378
Working Capital Days49554282237041,084234265101-440506
ROCE %13%15%24%-4%-54%-58%-118%-53%-36%-87%-80%

Guidance history

How Suven Life Sciences's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q3 FY20 call →10–20%FlatPlannedPlanned—
Q2 FY20 call →10–20%FlatPlanned——
Q4 FY19 call →10–20%FlatPlannedNone plannedRising

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

27out of 100

Momentum score · price trend

27 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,947 stocks
Last 12 months+48.3%83%
Last 6 months−0.3%45%
Last 3 months−21.0%9%

The price is 31.5% below its all-time high of ₹392.05 (31 Aug 2026). Stocks more than 20% below their peak have their score halved, so 53 became 27.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,947 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Suven Life Sciences: 0.4 × 83 + 0.4 × 45 + 0.2 × 9 = 53, halved to 27 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 17 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Suven Life Sciences: frequently asked questions

What is Suven Life Sciences share price today?

Suven Life Sciences last traded at ₹268.65, with a market capitalisation of ₹7,591 Cr.

What were Suven Life Sciences's latest quarterly results?

For the quarter ended Sep 2026, Suven Life Sciences reported revenue of ₹1 Cr (+30% year on year) and net profit of ₹-107 Cr, with an operating margin of -9242%.

Is Suven Life Sciences's profit growing?

Net profit was ₹-107 Cr in Sep 2026 against ₹-77 Cr in Sep 2025.

What is Suven Life Sciences's EPS?

Suven Life Sciences's earnings per share for the quarter ended Sep 2026 was ₹-3.78.

What is the promoter holding in Suven Life Sciences?

Promoters held 65.47% of Suven Life Sciences in Sep 2026 (−4.61 pp versus Jun 2026).

How much do FIIs and DIIs hold in Suven Life Sciences?

In Sep 2026, foreign institutional investors held 0.45% and domestic institutions (including mutual funds) held 2.17% of Suven Life Sciences.

What is Suven Life Sciences's ROE and ROCE?

Suven Life Sciences's return on equity is -81.5% and its return on capital employed is -79.5%.

Does Suven Life Sciences pay a dividend?

Suven Life Sciences's dividend yield is 0% at the current price; see the Suven Life Sciences dividends page for past payouts.

Which sector does Suven Life Sciences belong to?

Suven Life Sciences is in the Healthcare Services sector. Its peer comparison and sector ranking are on this page.

What did Suven Life Sciences's management say on the latest earnings call?

Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Suven Life Sciences's management.

How does Arthneeti AI analyse Suven Life Sciences?

Arthneeti reads Suven Life Sciences's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.